Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 in subjects with locally advanced or metastatic pancreatic cancer.